| |
| | European Patent Office Affirms Validity of Claims in Aquila's European Patent Covering Stimulon(R) Technology (Site not responding. Last check: 2007-10-08) |
 | | Aquila successfully defended its patent against oppositions by two companies, CSL Limited of Parkville, Victoria, Australia and Seed Capital Investments (SCI) B.V. of Utrecht, The Netherlands, following a 1-day hearing of oral arguments against the patent. |
 | | Aquila's corporate partners, which include SmithKline Beecham, Pasteur Merieux Connaught, Wyeth Lederle, Vaxgen, Bristol-Myers Squibb (Progenics Pharmaceuticals) and Virbac S.A., have licensed QS-21 and other Stimulon(R) adjuvants for use in products targeted at a variety of human diseases. |
 | | In addition, Aquila has a U.S. patent covering chemical modifications to the Company's proprietary Stimulon(R) adjuvants, including QS-21, issued by the U.S. Patent and Trademark Office in December of 1996. |
| www.findwealth.com /european-patent-office-affirms-validity-85399pr.html (655 words) |
|